NVO241227C120000
- 0.02
- 0.000.00%
Novo-Nordisk A/S Newsroom
Jim Cramer Says Novo Nordisk A/S (NVO) Can't Exceed Eli Lilly
Novo Nordisk Is 'Losing Its Pep' in GLP-1 Race: BMO Analyst
Novo Nordisk (NVO) Stock Drops Despite Market Gains: Important Facts to Note
Novo-Nordisk A/S Options Spot-On: On December 24th, 32,364 Contracts Were Traded, With 453.78K Open Interest
Weight-loss Drugs in 2025, Auto Industry Outlook: Market Domination
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk Shares Rally Despite Setback in Obesity Drug Trial Results
Top Gap Ups and Downs on Monday: TSM, HMC, GFI and More
FDA Approves First Generic of Novo Nordisk's Victoza
Novo-Nordisk A/S Options Spot-On: On December 23rd, 100.63K Contracts Were Traded, With 599.3K Open Interest
Tech Stocks Eye Christmas Gains, Microstrategy Tumbles As Bitcoin Dips To $93,000: What's Driving Markets Monday?
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
Today's Pre-Market Movers and Top Ratings | NVO, TSLA, TRAW and More
Express News | BMO Capital Maintains Outperform on Novo Nordisk, Lowers Price Target to $105
Novo Nordisk Analyst Ratings
Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark
Stocks Mostly Down Pre-Bell Ahead of Holiday-Shortened Trading Week; Asia, Europe Up
AlphaValue/Baader Europe: Novo Nordisk's New Obesity Drug Holds Promise Despite Disappointing Late-Stage Data
Gerresheimer Revenue Unlikely to Be Impacted by Novo Nordisk's CagriSema Data -- Market Talk